NYSE:APHAAphria Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aphria Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.47 -0.19 (-4.08 %) (As of 08/7/2020 04:00 PM ET) Add Compare Share Today's Range$4.38Now: $4.47▼$4.6450-Day Range$4.07MA: $4.67▼$6.0052-Week Range$1.95Now: $4.47▼$7.14Volume8.43 million shsAverage Volume6.74 million shsMarket Capitalization$1.29 billionP/E Ratio49.67Dividend YieldN/ABeta2.19 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInstitutional OwnershipHeadlinesSocial Media Aphria Inc. produces and sells medical cannabis in Canada and internationally. The company offers sativa, indica, and hybrid medical marijuana products, as well as cannabis oils. It serves patients and health professionals. The company also sells its products online. Aphria Inc. is headquartered in Leamington, Canada.Read More Beat the Market (BTM) Rank™ 4.4 Analyst's Opinion Consensus RatingAphria has received a consensus rating of Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.83, Aphria has a potential upside of 97.5% from its current price of $4.47.Amount of Analyst CoverageAphria has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.8 Community Rank Outperform VotesAphria has received 176 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAphria has received 137 “underperform” votes. (Add your “underperform” vote.)Community SentimentAphria has received 56.23% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Aphria and other stocks. Vote “Outperform” if you believe APHA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe APHA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAphria does not currently pay a dividend.Dividend GrowthAphria does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aphria insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 9.57% of the stock of Aphria is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aphria are expected to decrease in the coming year, from ($0.03) to ($0.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aphria is 49.67, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 18.35.Price to Earnings Ratio vs. SectorThe P/E ratio of Aphria is 49.67, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 32.88.Price to Book Value per Share RatioAphria has a P/B Ratio of 0.85. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.57 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSE Industry Medicinals & botanicals Sub-IndustryN/A SectorMedical Current SymbolNYSE:APHA Previous Symbol CUSIPN/A CIKN/A Webaphriainc.com PhoneN/ADebt Debt-to-Equity Ratio0.25 Current Ratio5.19 Quick Ratio3.73Price-To-Earnings Trailing P/E Ratio49.67 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$179.29 million Price / Sales7.18 Cash FlowN/A Price / Cash FlowN/A Book Value$5.23 per share Price / Book0.85Profitability EPS (Most Recent Fiscal Year)($0.11) Net Income$-12,480,000.00 Net Margins5.75% Return on Equity-0.30% Return on Assets-0.21%Miscellaneous Employees300 Outstanding Shares287,845,000Market Cap$1.29 billion Next Earnings Date10/20/2020 (Estimated) OptionableNot Optionable $4.47 -0.19 (-4.08 %) (As of 08/7/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive APHA News and Ratings via Email Sign-up to receive the latest news and ratings for APHA and its competitors with MarketBeat's FREE daily newsletter. Aphria (NYSE:APHA) Frequently Asked Questions How has Aphria's stock been impacted by COVID-19 (Coronavirus)? Aphria's stock was trading at $2.70 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, APHA stock has increased by 65.6% and is now trading at $4.47. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Aphria? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aphria in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aphria. When is Aphria's next earnings date? Aphria is scheduled to release its next quarterly earnings announcement on Tuesday, October 20th 2020. View our earnings forecast for Aphria. How were Aphria's earnings last quarter? Aphria Inc (NYSE:APHA) released its quarterly earnings data on Tuesday, April, 14th. The company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.06. The company had revenue of $144.40 million for the quarter, compared to the consensus estimate of $130.74 million. Aphria had a negative return on equity of 0.30% and a net margin of 5.75%. Aphria's revenue for the quarter was up 96.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.20) earnings per share. View Aphria's earnings history. What price target have analysts set for APHA? 8 analysts have issued 12-month target prices for Aphria's shares. Their forecasts range from $7.00 to $11.00. On average, they expect Aphria's stock price to reach $8.83 in the next twelve months. This suggests a possible upside of 97.5% from the stock's current price. View analysts' price targets for Aphria. Has Aphria been receiving favorable news coverage? News articles about APHA stock have trended very positive on Saturday, according to InfoTrie. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aphria earned a media sentiment score of 4.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news about Aphria. Who are some of Aphria's key competitors? Some companies that are related to Aphria include Cronos Group (CRON), USANA Health Sciences (USNA), Aurora Cannabis (ACB), Tilray (TLRY), Canopy Rivers (RIV), Chromadex (CDXC), Mediwound (MDWD), Sundial Growers (SNDL), Happiness Biotech Group (HAPP), Natural Alternatives International (NAII), Mannatech (MTEX), Cyanotech (CYAN), FitLife Brands (FTLF), True Drinks (TRUU) and GLG Life Tech (GLGLF). View all competitors. What other stocks do shareholders of Aphria own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aphria investors own include Aurora Cannabis (ACB), Canopy Growth (CGC), Cronos Group (CRON), Tilray (TLRY), NVIDIA (NVDA), Alibaba Group (BABA), OrganiGram (OGI), Advanced Micro Devices (AMD), HEXO (HEXO) and Charlotte's Web (CWBHF). Who are Aphria's key executives? Aphria's management team includes the following people: Mr. Carl A. Merton, Chief Financial OfficerMs. Megan McCrae, Director of MarketingMr. Irwin D. Simon, Interim CEO & ChairmanMr. Jakob Ripshtein, PresMr. Gary Leong, Chief Science Officer (Age 54) What is Aphria's stock symbol? Aphria trades on the New York Stock Exchange (NYSE) under the ticker symbol "APHA." Who are Aphria's major shareholders? Aphria's stock is owned by many different retail and institutional investors. Top institutional shareholders include Intact Investment Management Inc. (0.38%), AdvisorShares Investments LLC (0.20%), Swiss National Bank (0.19%), CIBC Asset Management Inc (0.06%), Actinver Wealth Management Inc. (0.04%) and Hilton Capital Management LLC (0.04%). Which institutional investors are selling Aphria stock? APHA stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Actinver Wealth Management Inc., and AE Wealth Management LLC. Which institutional investors are buying Aphria stock? APHA stock was purchased by a variety of institutional investors in the last quarter, including Intact Investment Management Inc., AdvisorShares Investments LLC, Swiss National Bank, Hilton Capital Management LLC, Eastern Bank, Glassman Wealth Services, Cambridge Investment Research Advisors Inc., and Zurcher Kantonalbank Zurich Cantonalbank . How do I buy shares of Aphria? Shares of APHA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Aphria's stock price today? One share of APHA stock can currently be purchased for approximately $4.47. How big of a company is Aphria? Aphria has a market capitalization of $1.29 billion and generates $179.29 million in revenue each year. The company earns $-12,480,000.00 in net income (profit) each year or ($0.11) on an earnings per share basis. Aphria employs 300 workers across the globe. What is Aphria's official website? The official website for Aphria is aphriainc.com. How can I contact Aphria? Aphria's mailing address is 245 TALBOT STREET W., LEAMINGTON A6, N8H 1N8. This page was last updated on 8/8/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
